Abstract
Radioreceptor assay, a promising new tool for studying serum levels of neuroleptics and their biologically active metabolites, was used to elucidate the role of neuroleptic plasma levels in 24 chronic schizophrenic patients with a poor clinical response to standard treatment. Most of these 24 patients attained serum levels reportedly associated with improvement in more acute patients, suggesting that their lack of response was not due to relative absence of drug in serum. Alternative reasons for lack of response despite adequate plasma levels are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
